Gastroenterology

Gibble TH, Kosa K, Basnyat B, Martin S, Moses RE, Jha P, Dubinsky MC. Exploring patient-reported outcome measures to assess symptoms of moderately-to-severely active Crohn's disease in adult and adolescent patients: a qualitative study. J Patient Rep Outcomes. 2025 Nov 4;9(1):128. doi: 10.1186/s41687-025-00959-1


BACKGROUND:To explore patients’ experience of symptoms and impacts of Crohn’s disease (CD) and evaluate content validity of patient-reported outcome (PRO) measures in moderately-to-severely active CD.

Domenech E, Fortuny J, Martinez D, Tormos A, Huang Z, Hill DD, Weinstein C, Esslinger S, Krumme AA, Otero-Lobato M, Mines D, Gisbert JP, ENEIDA Study Group of GETECCU. Colectomy and neoplasia outcomes of patients with ulcerative colitis receiving golimumab: a post-authorisation safety study using the Spanish ENEIDA Registry. Pharmacoepidemiol Drug Saf. 2025 Aug;34(8):e70176. doi: 10.1002/pds.70176


BACKGROUND AND AIMS: Golimumab, an anti–tumour necrosis factor α agent, is indicated for moderate to severe ulcerative colitis. We conducted a post-authorisation safety study to evaluate the risk of (1) colectomy due to intractable disease and (2) advanced colonic neoplasia, under real-world conditions of golimumab use.

Hunter Gibble T, Sweeney C, Wolin D, McSorley D, Wang J, Moses R, Dubinsky M. Evaluation of the symptoms and clinical characteristics of crohn's disease and ulcerative colitis that affect healthcare providers' treatment choices. Crohns Colitis 360. 2024 Oct 5;6(4):otae053. doi: 10.1093/crocol/otae053


Yousif Z, Nangia A, Abeysinghe S, Jiang J, Sanchirico M, Fan T. Comparative efficacy of biologics for the induction of clinical remission and response in biologic-naïve patients with moderate-to-severe crohn's disease: outcomes from frequentist and bayesian network meta-analyses. Poster presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting 2024; October 29, 2024. Philadelphia, PA.


Ayodele O, Parikh RC, Esterberg E, Ajmera M, Goodwin B, Williams J, Desai NK, Katzka DA. Treatment patterns and persistent disease activity in patients with eosinophilic esophagitis: a retrospective cohort study. Gastro Hep Adv. 2024 Mar 2;3(5):659-70. doi: 10.1016/j.gastha.2024.02.007


BACKGROUND AND AIMS: Limited real-world nontertiary care evidence on the patient therapeutic journey and disease burden of eosinophilic esophagitis (EoE) exists. The aim was to collect real-world data on the EoE patient journey across different age groups.

Fermann GJ, Cash BD, Coelho-Prabhu N, Maegele M, Bingisser R, Sehgal V, Cohen AT, Golden AH, Russo J, Price M, Mangel A, Koch B, Christoph MJ, Milling, Jr. TJ. Definition of factor Xa inhibitor–related, life-threatening gastrointestinal bleeding and guidance on when to use reversal therapy: a Delphi panel. J Am Coll Emerg Physicians Open. 2023 Oct 2;4(5):e13043. doi: 10.1002/emp2.13043


OBJECTIVE: To define and contextualize life-threatening gastrointestinal (GI) bleeding in the setting of factor Xa (FXa) inhibitor therapy and to derive a consensus-based, clinically oriented approach to the administration of FXa inhibitor reversal therapy.

Domenech E, Fortuny J, Martinez D, Tormos A, Huang Z, Hill D, Weinstein C, Esslinger S, Krumme A, Mines D, Gisbert J. A post-authorization safety study of golimumab in ulcerative colitis using the Spanish ENEIDA registry (MK8259-042). Poster presented at the 2024 ISPE Annual Meeting; August 28, 2024. Berlin, Germany.


Gibble TH, Kosa K, Basnyat B, Martin S, Moses R, Dubinsky M. Cognitive debriefing of a patient-reported outcome measure for abdominal pain and loose stool frequency in Crohn's disease. Poster presented at the European Crohn's and Colitis Organisation (ECCO) 2024; February 21, 2024. Stockholm, Sweden. [abstract] J Crohns Colitis. 2024 Jan; 18(Suppl 1):i572.


Gibble TH, Kosa K, Basnyat B, Martin S, Moses R, Dubinsky M. Patient perspectives on symptoms and impacts in Crohn's disease: results from qualitative research. Poster presented at the European Crohn's and Colitis Organisation (ECCO) 2024; February 21, 2024. Stockholm, Sweden. [abstract] J Crohns Colitis. 2024 Jan; 18(Suppl 1):i265.


Gold BD, Goodwin B, Davis K, Sweeney C, Reynolds M, Jiang J, Fan T, Boules M, Chen S, Katzka DA. Health-related quality of life and perceived stigma in eosinophilic esophagitis: a real-world, US, web-based survey. Gastro Hep Adv. 2024;3(8):1087-97. doi: 10.1016/j.gastha.2024.07.015


OBJECTIVES: The impact of eosinophilic esophagitis (EoE) on the daily life and ability to function in adolescents and adults with EoE in the United States of America was examined.

Subscribe to Gastroenterology